Loading
Adding nivolumab to chemotherapy, or combining nivolumab with ipilimumab without chemotherapy, lengthened survival compared with chemotherapy alone in advanced oesophageal squamous cell carcinoma, with the largest gains in PD-L1-positive tumours.
Phase 3 trial of 970 patients with previously untreated advanced oesophageal squamous cell carcinoma randomised to nivolumab plus fluorouracil-cisplatin, nivolumab plus ipilimumab, or chemotherapy alone.
In tumours with PD-L1 expression of 1 percent or more, median overall survival was 15.4 months with nivolumab-chemotherapy and 13.7 months with nivolumab-ipilimumab against 9.1 months with chemotherapy (hazard ratios 0.54 and 0.64); benefit was also seen in the overall population.
Nivolumab plus chemotherapy or nivolumab plus ipilimumab are first-line standards for advanced oesophageal squamous cell carcinoma, joining pembrolizumab-chemotherapy from KEYNOTE-590.
Shares Oesophageal squamous cell carcinoma, Nivolumab, New England Journal of Medicine.
Shares Oesophageal squamous cell carcinoma, New England Journal of Medicine.
Shares CheckMate 648, Nivolumab.